• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Silo Pharma Inc (NQ: SILO )

    1.130 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Silo Pharma Inc

    < Previous 1 2 3 4 5 6 Next >
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Promising Results from Testing of Ketamine-Loaded Implant for Chronic Pain Relief
    Via Investor Brand Network
    Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports on FDA Pre-IND Meeting to Advance Development of Lead Program
    Via Investor Brand Network
    Exposures Product Safety
    Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic
    Via Investor Brand Network
    Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Agreement to Launch New Study of SPU-16 Homing Peptide for Multiple Sclerosis
    Via Investor Brand Network
    Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference
    Via Investor Brand Network
    Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
    From Silo Pharma, Inc.
    Via GlobeNewswire
    Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering
    Via Investor Brand Network
    Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters Device and CMC Development Master Plan to Support IND-Enabling Study of SPC-15
    Via Investor Brand Network
    Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Exclusive Global License to Develop, Manufacture, Commercialize Alzheimer Drug
    Via Investor Brand Network
    Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters License Agreement with Columbia University for Lead Candidate Targeting PTSD, Stress-Induced Anxiety Disorders
    Via Investor Brand Network
    Exposures Product Safety
    Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Collaborates with CRO Partner to Advance SPC-15 for PTSD
    Via Investor Brand Network
    Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
    From Silo Pharma, Inc.
    Via GlobeNewswire
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic
    Via Investor Brand Network
    Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
    From Silo Pharma, Inc.
    Via GlobeNewswire
    Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Registered Direct Offering Estimated to Reach $2M
    Via Investor Brand Network
    Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Pre-IND Submission for Proprietary Treatment for PTSD, Anxiety
    Via Investor Brand Network
    Exposures Product Safety
    Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
    From Silo Pharma, Inc.
    Via GlobeNewswire
    Silo Pharma’s (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
    Via AB Newswire
    Exposures Product Safety
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse
    Via Investor Brand Network
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.